Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 48, 2008, Pages 19018-19023

  Basu, Sanjay ^a   Chapman, Gretchen B ^b   Galvani, Alison P ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

Game theory; Mathematical modeling

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; HEALTH CARE UTILIZATION; HEALTH SURVEY; PARENT; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SEXUAL BEHAVIOR; THEORETICAL MODEL; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; CHILD; FEMALE; GAME THEORY; HUMANS; MALE; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

HUMAN PAPILLOMAVIRUS;

EID: 57749106718     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0808114105     Document Type: Article

References (59)

1. National Cancer Institute (2008) Cervical cancer. Available at http://www.cancer.gov/cancerinfo/types/cervical (accessed August 1, 2008).
2. Centers for Disease Control and Prevention (2007) Quadrivalent human papillomavirus vaccine. Recommendations of the advisory committee on immunization Practices (ACIP). MMWR 56(RR02):1-24.
3. Dasbach EJ, Elbasha EH, Insinga RP (2006) Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28:88-100.
4. Kim JJ, et al. (2007) Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 166:137-150.
5. Van de Velde N, Brisson M, Boily MC (2007) Modeling human papillomavirus vaccine effectiveness: Quantifying the impact of parameter uncertainty. Am J Epidemiol 165:762-775.
6. Colgrove J (2006) The ethics and politics of compulsory HPV vaccination. N Engl J Med 355:2389-2391.
7. Elbasha EH, Dasbach EJ, Insinga RP (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13:28-41.
8. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE (2008) Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 14:244-251.
9. Weeg C (July 28, 2008) A lifesaving tool against cervical cancer remains underused. New York Times, Health Section.
10. Anderson RM, May RM (1991) Infectious Diseases of Humans: Dynamics and Control (Oxford Univ Press, Oxford).
11. Galvani AP, Reluga TC, Chapman GB (2007) Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proc Natl Acad Sci USA 104:5692-5697.
12. Bauch CT (2005) Imitation dynamics predict vaccinating behaviour. Proc Biol Sci 272:1669-1675.
13. Bauch CT, Earn DJ (2004) Vaccination and the theory of games. Proc Natl Acad Sci USA 101:13391-13394.
14. Bauch CT, Galvani AP, Earn DJD (2003) Group interest versus self-interest in smallpox vaccination policy. Proc Natl Acad Sci USA 100:10564-10567.
15. Reluga TC, Bauch C, Galvani AP (2006) Evolving public perceptions and stability in vaccine uptake. Math Biosci 204:185-198.
16. Nash J (1950) Equilibrium points in n-person games. Proc Natl Acad Sci USA 36:48-49.
17. Morgenstern O, von Neumann J (1947) The Theory of Games and Economic Behavior (Princeton Univ Press, Princeton).
18. Goldie SJ, et al. (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96:604-615.
19. Sanders GD, Taira AV (2003) Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9:37-48.
20. Taira AV, Neukermans CP, Sanders GD (2004) Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10:1915-1923.
21. Kaiser Family Foundation (2008) HPV Vaccine: Implementation and financing policy in the U.S. (Kaiser Family Foundation, Washington D.C.).
22. Edmunds M, Coye MJ, eds (1998) America's Children: Health Insurance and Access to Care (National Academies Press, Washington D.C.).
23. Health Care Financing Administration (2003) Charges for Vaccine Administration Under the Vaccines for Children (VFC) Program (U.S. Department of Health and Human Services, Washington D.C.).
24. Salganicoff A (2006) HPV Vaccine Financing Issues for Low-income Women and Girls (California Women's Health Council, Sacramento, CA).
25. Arizona State Legislature (2007) Program Summary: Department of Health Services Vaccines (JLBC, Phoenix).
26. Friedman AL, Shepeard H (2007) Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: Findings from CDC focus group research and implications for practice. Health Educ Behav 34:471-485.
27. Goldie SJ, et al. (2003) A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 106:896-904.
28. Newall AT, Beutels P, Wood JG, Edmunds WJ, Macintyre CR (2007) Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 7:289-296.
29. Elbasha EH, Galvani AP (2005) Vaccination against multiple HPV types. Math Biosci 197:88-117.
30. Gold M, Siegel J, Russell L, Weinstein M (1996) Cost-Effectiveness in Health and Medicine: Report of the Panel on Cost-Effectiveness in Health and Medicine. (Oxford Univ Press, New York).
31. U.S. Census Bureau (2006) Annual Estimates of the Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2005 (U.S. Census Bureau, Washington D.C.).
32. Welton NJ, Ades AE (2005) Estimation of Markov chain transition probabilities and rates from fully and partially observed data: Uncertainty propagation, evidence synthesis, and model calibration. Med Decis Making 25:633-645.
33. Dunne EF, et al. (2006) Prevalence of HPV infection among females in the United States. JAMA 297(8):813-819.
34. Raftery AE, Lewis SM, eds (1996) Implementing MCMC. (Chapman and Hall, London).
35. Gelman A, Carlin JB, Stern HS, Rubin DB (2004) Bayesian Data Analysis (Chapman & Hall/CRC, Boca Raton).
36. Brooks SP, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7:434-455.
37. National Cancer Institute (2006) Surveillance Epidemiology and End Results Program (National Institutes of Health, Bethesda).
38. Insinga RP, Dasbach EJ, Myers ER (2003) The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36:1397-1403.
39. Insinga RP, Glass AG, Rush BB (2004) Diagnoses and outcomes in cervical cancer screening: A population-based study. Am J Obstet Gynecol 191:105-113.
40. Basu S, Galvani AP (2007) Re: "Multiparameter calibration of a natural history model of cervical cancer." Am J Epidemiol 166:983; author reply 983-984.
41. Jacquez JA (1985) Identifiability and model distinguishability. Compartmental Analysis in Biology and Medicine (University of Michigan Press, Ann Arbor), pp 309-354.
42. Greenland S, Robins JM (1986) Identifiability, exchangeability, and epidemiological confounding. International journal of epidemiology 15:413-419.
43. Grassly NC, Fraser C (2008) Mathematical models of infectious disease transmission. Nat Rev Microbiol 6:477-487.
44. Centers for Disease Control and Prevention (2008) CDC Vaccine Price List (CDC, Atlanta).
45. Insinga RP (2006) Annual productivity costs due to cervical cancer mortality in the United States. Womens Health Issues 16:236-242.
46. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL (2004) The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 36:11-19.
47. Leigh WA (2003) Making the Case: The Cost to State and Local Governments of Teen Pregnancy and Teen Pregnancy Prevention (NOAPPP, Arlington).
48. Bureau of Labor Statistics (2006) Consumer Price Indexes. (U.S. Department of Labor, Washington D.C.).
49. Sanders GD, et al. (2005) Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352:570-585.
50. Stratton K, Durch J, Lawrence R, Committee to Study Priorities for Vaccine Development (2000) Vaccines for the 21st Century: A Tool for Decisionmaking. (Institute of Medicine (U.S.), Washington D.C.).
51. Institute for Clinical Research and Health Policy Studies (2008) Cost-Effectiveness Analysis Registry (Tufts University, Boston).
52. Romer D (2005) Advanced Macroeconomics (McGraw-Hill/Irwin, New York).
53. Reluga TC, Medlock J, Poolman E, Galvani AP (2007) Optimal timing of disease transmission in an age-structured population. Bull Math Biol 69:2711-2722.
54. Stein M (1987) Large sample properties of simulations using Latin Hypercube Sampling. Technometrics 29:143-151.
55. Blower SM, Dowlatabadi H (1994) Sensitivity and uncertainty analysis of complex models of disease transmission - an HIV model, as an example. Int Stat Rev 62:229-243.
56. DeNavas C, Proctor BD, Mills RJ (2004) Income, Poverty, and Health Insurance Coverage in the United States: (U.S. Census Bureau, Washington D.C.).
57. Paquette RL, et al. (1993) Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 72:1272-1280.
58. Centers for Disease Control and Prevention (2006) National Immunization Survey (National Immunization Program, Atlanta).
59. Kirkpatrick S, Gelatt CD, Vecchi MP (1983) Optimization by simulated annealing. Science 220:671-680.